NatureCell America Receives FDA Approval for Adult Autism Stem Cell Therapy

Initiation of Phase 1 Trials Marks Progress in Developing New Treatment Option

Apr. 15, 2026 at 1:09pm

Got story updates? Submit your updates here. ›

A highly detailed, translucent X-ray-style image revealing the intricate neural structures and connections within the human brain, conceptually representing the complex biological mechanisms involved in autism spectrum disorder.A new stem cell therapy aims to address the underlying neurological causes of autism in adults, offering hope for a breakthrough treatment.Los Angeles Today

NatureCell America, a subsidiary of biotechnology company NatureCell Co., Ltd., has received Investigational New Drug (IND) clearance from the U.S. Food and Drug Administration for its AstroStem-AU therapy, an autologous adipose-derived mesenchymal stem cell treatment for adults with Autism Spectrum Disorder (ASD). This approval allows the company to begin Phase 1 clinical trials to assess the safety and potential efficacy of the therapy, which aims to address the underlying biological mechanisms of ASD rather than just manage symptoms.

Why it matters

Despite ASD affecting an estimated 1-2% of the adult population in the U.S., treatment options for adults remain extremely limited, with no therapies addressing the root causes of the condition. AstroStem-AU represents a potential breakthrough in addressing this significant unmet medical need and could establish a new premium segment within the growing $25-30 billion global autism treatment market.

The details

AstroStem-AU is derived from mesenchymal stem cells cultured from a patient's own adipose tissue and is designed to be administered through a series of 10 intravenous infusions. NatureCell has prior clinical experience using a similar repeated intravenous dosing regimen in Alzheimer's disease trials, establishing a meaningful safety profile that is expected to support the upcoming Phase 1 trial in adult ASD. The Phase 1 study will primarily assess safety and tolerability, while also exploring early indicators of efficacy, including potential improvements in behavior, cognitive function, and overall quality of life.

  • NatureCell America received IND clearance from the FDA on April 15, 2026.
  • The company plans to initiate a Phase 1 clinical trial for AstroStem-AU in the near future.

The players

NatureCell Co., Ltd.

A biotechnology company focused on adult stem cell therapies, led by Chairman Jeong-chan Ra.

NatureCell America

The U.S. subsidiary of NatureCell Co., Ltd. that received the IND clearance for AstroStem-AU.

U.S. Food and Drug Administration (FDA)

The regulatory agency that granted the IND clearance for AstroStem-AU.

Got photos? Submit your photos here. ›

What they’re saying

“This IND clearance represents a pivotal step toward developing a treatment for adult autism.”

— Jeong-chan Ra, Chairman, NatureCell Co., Ltd.

“Building on the safety data established in our Alzheimer's studies, we are eager to evaluate both the safety and therapeutic potential of AstroStem-AU in this new indication.”

— Jeong-chan Ra, Chairman, NatureCell Co., Ltd.

What’s next

NatureCell America plans to initiate a Phase 1 clinical trial for AstroStem-AU in the near future and intends to pursue Regenerative Medicine Advanced Therapy (RMAT) designation from the FDA, which could provide access to expedited development pathways.

The takeaway

The approval of AstroStem-AU for clinical trials represents a significant step forward in addressing the unmet medical needs of adults with Autism Spectrum Disorder, a population that has historically had limited treatment options. If successful, this stem cell therapy could establish a new standard of care and open up a new premium segment within the growing global autism treatment market.